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Abstract Apocynin (4-hydroxy-3-methoxy-acetophenone) is a
potent intracellular inhibitor of superoxide anion production in
neutrophils. In this study, we studied the effect of apocynin on the
regulation of the antioxidant glutathione (GSH) and activation
of the transcription factor AP-1 in human alveolar epithelial cells
(A549). Apocynin enhanced intracellular GSH by increasing
Q-glutamylcysteine synthetase activity in A549 cells. Apocynin
also increased the expression of Q-GCS heavy subunit mRNA.
This was associated with increased AP-1 DNA binding as
measured by the electrophoretic mobility shift assay. These data
indicate that apocynin displays antioxidant properties, in part, by
increasing glutathione synthesis through activation of AP-1.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Apocynin (4-hydroxy-3-methoxy-acetophenone) is a con-
stituent of root extracts of the medicinal herb Picroria kurroa
which grows in the Himalayan mountains [1]. Apocynin is
known to be a potent intracellular inhibitor of superoxide
anion (O3c2 ) production by activated neutrophils and eosino-
phils [2,3]. It also protects secretory leukocyte protease inhib-
itor (SLPI) from oxidative inactivation [3]. Furthermore,
apocynin improves the e⁄cacy of SLPI in lipopolysacchar-
ide-induced emphysema in hamsters [2]. Apocynin possesses
anti-in£ammatory properties and can decrease the adhesion of
monocytic U937 cells to human umbilical vein endothelial
cells (HUVEC) induced by tumour necrosis factor-K (TNF-
K) through suppression of the adhesion molecule VCAM-1
[4]. It also decreases collagen-induced plasma interleukin-6
levels in rats [5]. These e¡ects may be mediated by a transcrip-
tional mechanism involving transcription factors such as acti-
vator protein-1 (AP-1). Furthermore, recent study has indi-
cated that apocynin inhibits endotoxin-induced bronchial
hyperresponsiveness to substance P and plasma levels of lipid
peroxides in guinea pigs [6].
The tripeptide glutathione (GSH) or L-Q-glutamyl-L-cyste-
inylglycine is a ubiquitous cellular non-protein sulphydryl
which has an important role in maintaining intracellular redox
balance and is involved in the detoxi¢cation of peroxides, free
radicals, heavy metals and xenobiotics [7].
GSH synthesis is controlled by two rate-limiting factors.
One is the enzyme Q-glutamylcysteine synthetase (Q-GCS),
which catalyses the ¢rst reaction of de novo GSH synthesis.
The other is the availability of cysteine [7], a breakdown prod-
uct of extracellular GSH by the membrane-bound enzyme
Q-glutamyltranspeptidase (Q-GT) [8]. We have recently shown
that GSH synthesis is induced in cells exposed to oxidative
stress [9,10], as an adaptive defence response. We have also
recently demonstrated that a putative AP-1 transcription fac-
tor binding site is necessary for the regulation of the catalytic
Q-GCS-HS gene promoter [11,12].
In this study, we hypothesise that the antioxidant properties
of apocynin may result from an increase in the GSH synthesis
in human alveolar epithelial cells. Therefore, we studied the
levels of GSH, Q-GCS and Q-GT activities and Q-GCS-HS
mRNA expression in response to apocynin in a human type
II alveolar epithelial cell line (A549). We also investigated
the e¡ects of apocynin on the DNA binding of AP-1 in these
cells.
2. Materials and methods
Unless otherwise stated, all of the biochemical reagents used in this
study were purchased from Sigma Chemical Co. (Poole, UK); cell
culture media were purchased from Gibco-BRL (Paisley, UK). Apo-
cynin was purchased from Aldrich Chemical Co. (Dorset, UK).
2.1. Epithelial cell exposure to apocynin
The human type II alveolar epithelial cell line, A549 (ECACC No.
86012804), was maintained in continuous culture at 37‡C, 5% CO2 in
Dulbecco’s modi¢ed minimum essential medium (DMEM) containing
L-glutamine (2 mM), penicillin (100 U/ml)/streptomycin (100 Wg/ml)
and 10% foetal bovine serum (FBS).
Monolayers of con£uent A549 epithelial cells were prepared by
seeding 1U106 cells/well in a 6-well plate and reculturing in DMEM
with 10% FBS at 37‡C, 5% CO2 for 24 h. Con£uent monolayers were
rinsed twice with DMEM and exposed to apocynin (100 or 500 WM)
for 1 and 24 h in 2 ml of full medium at 37‡C, 5% CO2. Thereafter,
the monolayers were washed twice with cold PBS, detached with
trypsin-EDTA (0.05% w/v) solution and washed with full DMEM
at 250Ug for 5 min, after which the cells were resuspended in 1 ml
PBS. Cell viability was determined by trypan blue exclusion.
2.2. GSH and GSSG assays
The epithelial cells were centrifuged at 250Ug for 5 min at 4‡C, and
the cell pellets were resuspended in 1 ml of cold 0.6% (w/v) sulpho-
salicylic acid and 0.1% (v/v) Triton X-100 in PBS, sonicated on ice,
homogenised with a Te£on pestle, and vortexed vigorously. The cells
were then centrifuged at 4000Ug for 10 min at 4‡C. The supernatant
was immediately stored at 320‡C or used immediately in the soluble
GSH assay by the 5,5P,dithiobis-(2-nitrobenzoic acid) (DTNB)-GSSG
reductase recycling method described by Tietze [13]. In the GSSG
assay, supernatant was treated with 2-vinylpyridine and triethanol-
amine as previously described [14], and thereafter was used in the
assay for GSH as described above.
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2.3. Q-GCS and Q-GT assays
Cell extracts for Q-GCS activity were prepared 1 or 24 h after
apocynin exposure. Cultured cells were washed with ice-cold PBS,
scraped into PBS and collected by centrifugation at 250Ug for
5 min at 4‡C. After two additional washes with PBS, the cells were
resuspended in 100 mM potassium phosphate bu¡er, pH 7.4, soni-
cated and homogenised using a Te£on pestle on ice with Triton X-
100, to a ¢nal concentration of 0.1% (v/v). The extracts were spun at
13 000Ug for 15 min at 4‡C. The supernatants were recovered and
then stored at 4‡C. Protein concentrations were determined using the
bicinchoninic acid reagent assay (Pierce, Chester, UK).
Q-GCS activity was assayed by the method described by Seelig and
Meister [15] using a coupled assay with pyruvate kinase and lactate
dehydrogenase. The rate of decrease in absorbance at 340 nm was
followed at 37‡C. Enzyme speci¢c activity was de¢ned as Wmol of
NADH oxidised/min/mg protein, which is equal to 1 IU.
In the Q-GT activity assay, whole cells were suspended in 100 mM
Tris-HCl bu¡er. Q-GT activity was assayed with the method of Tate
and Meister [16] using 0.1 M glycyl-glycine and 5 mM L-Q-glutamyl-p-
nitroanilidine. The rate of formation of p-nitroaniline was recorded as
the change in absorbance at 410 nm, 37‡C for 1 min. Puri¢ed Q-GT
was used as a standard, and 1 IU of Q-GT was de¢ned as the amount
in Wmol of p-nitroaniline released from L-Q-glutamyl-p-nitroaniline/
min/mg protein.
2.4. Isolation of RNA and reverse transcription
RNA was isolated from A549 cells using the Trizol reagent (Life
Technologies, Paisley, UK). Total RNA was reverse transcribed ac-
cording to the manufacturer’s instructions (Life Technologies, cat. no.
8025SA). The resultant cDNA was stored at 320‡C until required.
2.5. Analysis of Q-GCS-HS mRNA by the polymerase chain reaction
(PCR)
Oligonucleotide primers were chosen using the published sequence
of human Q-GCS-HS cDNA [17] and human glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) [18] (Stratagene, Cambridge, UK).
The primers for Q-GCS-HS were synthesised by Oswel DNA Services,
University of Southampton, UK [11,12,19]. The sequences of the
primers used in the PCR were as follows: Q-GCS-HS (sense 5P-GTG
GTA CTG CTC ACC AGA GTG ATC CT-3P) and (anti-sense 5P-
TGA TCC AAG TAA CTC TGG ACA TTC ACA-3P) ; GAPDH
(sense 5P-CC ACC CAT GGC AAA TTC CAT GGC A-3P) and
(anti-sense 5P-TC TAG ACG GCA GGT CAG GTC AAC C-3P).
5 Wl of the reverse transcribed mixture (cDNA) was added directly
to the PCR mixture and used for the PCR reactions, which we have
previously described [9,10,19]. Bands were visualised by a UV trans-
illuminator and photograph negatives were scanned using a white/
ultraviolet transilluminator, UVP (Orme Technologies, Cambridge,
UK). The relative levels of the Q-GCS-HS mRNA (531 bp) were
normalised as a percentage of the intensity of the GAPDH bands
(600 bp). The pKS-hGCS plasmid (American Type Culture Collec-
tion, ATCC, Rockville, MD, USA., cat. no. 79023) was used as a
positive control for Q-GCS-HS. 50 fg was used for each experiment
to check the speci¢city of the PCR.
2.6. Preparation of nuclear extracts and the electrophoretic mobility
shift assay (EMSA)
Nuclear extracts were prepared by the method of Staal et al. [20].
The consensus oligonucleotides used were commercial AP-1-contain-
ing sequences (5P-CGC TTG ATG AGT CAG CCG GA-3P, 3P-CGC
AAC TAC TCA GTC GGC CTT-5P), which were obtained from
Promega. The oligonucleotides were end-labelled with [Q-32P]ATP us-
ing T4 polynucleotide kinase and [Q-32P]ATP (Promega). Binding re-
actions were carried out using 5 Wg of nuclear extract protein and 0.25
mg/ml poly(dI-dC).poly(dI.dC) (Pharmacia Biotech, St. Albans, UK),
in a 20 Wl binding bu¡er (Promega). The protein-DNA complexes
were resolved on 6% non-denaturing polyacrylamide gels at 100 V
for 3^4 h. The gels were then vacuum dried and autoradiographed
overnight with an intensifying screen at 380‡C. The gel was scanned
and bands analysed on a white/ultraviolet transilluminator UVP den-
sitometry (Orme Technologies, Cambridge, UK).
2.7. Statistical analysis
The data expressed as means þ S.E.M. Di¡erences between values
were compared by ANOVA.
3. Results
3.1. E¡ect of apocynin on GSH and GSSG levels in alveolar
epithelial cells
Exposure to 100 and 500 WM of apocynin signi¢cantly in-
creased GSH levels after 24 h in A549 epithelial cells by 71%
and 111%, respectively (Fig. 1). A similar increase was ob-
served after 1 h of treatment with both concentrations of
apocynin. GSSG levels were not a¡ected by either 100 or
500 WM apocynin treatment for 1 h (1.74 þ 1.16, 2.05 þ 1.51
nmol/106 cells, n = 4) and 24 h (1.81 þ 0.61, 2.08 þ 0.84 nmol/
106 cells, n = 4), respectively, in A549 cells, compared to con-
trol values (1 h 0.88 þ 0.36 and 24 h 1.17 þ 0.73 nmol/106 cells,
n = 4). Cell viability remained s 95% after all of the above
treatments.
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Fig. 1. E¡ect of apocynin on GSH levels in A549 type II alveolar
epithelial cells. A549 epithelial cells were incubated with 100 and
500 WM apocynin for 1 and 24 h. Each histogram represents the
mean and the bars the S.E.M. of 3^5 experiments. **P6 0.01,
***P6 0.001 compared with control values.
Table 1
E¡ects of apocynin on Q-GT activity in A549 alveolar epithelial cells
Treatment Q-GT activity (U/mg protein)
1 h 24 h
Control 0.09 þ 0.01 0.09 þ 0.01
Apocynin 100 WM 0.09 þ 0.02 0.11 þ 0.02
Apocynin 500 WM 0.10 þ 0.03 0.09 þ 0.02
A549 epithelial monolayers were treated with apocynin (100, 500 WM)
for 1 and 24 h. Data are expressed as mean þ S.E.M. (n=3). There are
no signi¢cant di¡erences compared with control values.
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3.2. E¡ect of apocynin on Q-GCS and Q-GT activities in alveolar
epithelial cells
Q-GCS activity was signi¢cantly elevated by 81% and 124%
by apocynin 100 and 500 WM treatment, respectively, at 24 h
in A549 cells, compared to control values (Fig. 2). A similar
increase was observed after 1 h of treatment with both con-
centrations of apocynin. The activity of Q-GT was not a¡ected
by either 100 or 500 WM apocynin treatment for 1 and 24 h
(Table 1).
3.3. E¡ect of apocynin on Q-GCS-HS mRNA expression
We investigated the mechanism of the e¡ect of apocynin
on GSH level and Q-GCS activity. Apocynin (100, 500 WM)
exposure signi¢cantly increased Q-GCS-HS mRNA expression
after 24 h without any signi¢cant increase at 1 h, compared to
GAPDH gene expression (Fig. 3A,B). The level of Q-GCS-HS
expression was increased by 142%, 183% by apocynin 100 and
500 WM treatment, respectively, at 24 h in A549 cells.
3.4. Role of AP-1 in the apocynin-mediated regulation of
Q-GCS-HS
To determine if AP-1 plays an important role in apocynin-
mediated Q-GCS-HS gene regulation, nuclear proteins were
isolated after 1 h of treatment with apocynin, and were incu-
bated with the DNA probe containing an AP-1 site. We found
that apocynin exposure increased AP-1 DNA binding activity
using this probe at 1 h exposure (Fig. 4A,B), in A549 cells,
compared to untreated cells. The speci¢city of the binding was
checked using 100-fold excess unlabeled AP-1 oligonucleoti-
des, and non-speci¢c oligonucleotides for NF-UB (data not
shown).
4. Discussion
Apocynin is a potent inhibitor of membrane-bound
NADPH oxidase and therefore it inhibits the production of
superoxide and hydrogen peroxide from stimulated neutro-
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Fig. 3. E¡ect of apocynin on Q-GCS-HS mRNA expression in A549
alveolar epithelial cells. Total RNA was isolated from control cells
and cells exposed to apocynin for 1 and 24 h. A: RNA was reverse
transcribed and used for PCR analysis of Q-GCS-HS mRNA as de-
scribed in Section 2. B: The numeric estimates of Q-GCS-HS
mRNA levels compared with the subsequent GAPDH bands from
the same sample. The histograms represent the relative intensities of
Q-GCS-HS mRNA to GAPDH bands, which were expressed as the
mean þ S.E.M. of three experiments each performed in duplicate.
***P6 0.001 compared with control levels.
Fig. 2. E¡ect of apocynin on Q-GCS enzyme activity in A549 alveo-
lar epithelial cells. A549 epithelial cells were incubated with 100 or
500 WM apocycin for 1 and 24 h. The histograms represent the
means and the bars the S.E.M. of 3^5 experiments. *P6 0.05,
**P6 0.01, ***P6 0.001, compared with control values.
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phils [3,21]. The therapeutic potential of apocynin (10 mg/kg)
in the lungs has been demonstrated in vivo in which apocynin
improved the e⁄cacy of elastase inhibitors to prevent the
development of experimental emphysema in animal models,
possibly by increasing the antioxidant potential of the lungs
[2]. In this study, we show that apocynin concentrations of
100 and 500 WM, which were easily achievable in in vivo
studies [2], increase the synthesis of the antioxidant GSH in
alveolar epithelial cells without altering GSSG levels suggest-
ing that apocynin itself does not cause oxidative stress. One
mechanism we considered to account for the elevation in GSH
was an increase in Q-GCS activity, the rate-limiting enzyme for
GSH biosynthesis. The results of this study demonstrated that
the increase in GSH levels was associated with an increase in
Q-GCS activity in A549 epithelial cells.
Although the enzyme Q-GT has been considered to be im-
portant in maintaining intracellular GSH, we found that
apocynin had no e¡ect on Q-GT activity in epithelial cells.
Thus our data suggest that Q-GT may not be involved in
apocynin-mediated GSH synthesis in alveolar epithelial cells.
Indeed we have previously shown that the increase in GSH
levels in epithelial cells is mainly due to transcriptional upre-
gulation of Q-GCS-HS mRNA in response to TNF-K and
oxidative stresses [10^12,22].
The levels of GSH and Q-GCS activity are regulated by the
expression of the Q-GCS-HS mRNA [23]. Recently, Rahman
et al. and others have demonstrated that phenolic antioxi-
dants, oxidants and chemotherapeutic agents can increase
GSH concentrations by induction of Q-GCS-HS expression
in various cell lines [9^12,24^27]. In this study, we show, for
the ¢rst time, that in human alveolar epithelial cells, Q-GCS-
HS gene expression is induced by apocynin. Similar increases
in GSH levels have been shown in bronchoalveolar lavage
£uid in rats treated with apocynin, which protected their lungs
against the deleterious e¡ects of ozone [28]. In addition,
Chander et al. reported that the herb Picroria kurroa (apo-
cynin) protected against Plasmodium berghei-infected Mas-
tomys natalensis by a mechanism involving activation of
GSH synthesis in the liver [29]. The mechanism of this anti-
oxidant protection was not investigated.
We have recently shown the critical role of an AP-1 site in
the regulation of the Q-GCS-HS [11,12]. To understand the
molecular mechanism of the transcriptional induction of glu-
tathione and Q-GCS-HS in response to apocynin, we studied
the activation of putative transcription factors AP-1 in A549
epithelial cells in response to apocynin. Activation of AP-1 is
known to be regulated by a variety of pro- and anti-oxidant
agents including quinones and acetophenones/catechols [30].
Exposure of alveolar epithelial cells to apocynin produced a
signi¢cant increase in the DNA binding activity of nuclear
protein, using AP-1 as consensus probe. Thus AP-1 transcrip-
tion factor is activated by apocynin treatment.
In conclusion, the present study demonstrates that apo-
cynin caused an increase in intracellular GSH content in hu-
man type II alveolar epithelial cells, Q-GCS activity and in-
duction of Q-GCS-HS. Our results also indicate that this
increased GSH synthesis appears to be regulated by an AP-
1-mediated mechanism leading to the up-regulation of Q-GCS-
HS. This data may have implications for apocynin treatment
in patients with in£ammatory lung diseases, since such treat-
ment may increase synthesis of the protective antioxidant
GSH.
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Fig. 4. E¡ect of apocynin on the regulation of AP-1 binding activity
in A549 alveolar epithelial cells. A549 cells were treated with apocy-
nin (100^500 WM) at the times indicated. A: Nuclear extracts were
prepared and analysed by the electrophoretic mobility shift assay
(EMSA) using 32P-labeled synthetic double-stranded oligonucleotides
containing AP-1. The DNA-protein complexes formed are indicated
(arrow) for AP-1. B: The numeric estimates of DNA binding levels
were compared with the control value set at 100%. The histograms
are expressed as the means and the bars the S.E.M. of three experi-
ments. **P6 0.01, compared with control values.
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